Clinical Significance of IgG vs IgM Antiphospholipid Antibodies in APS
IgG antiphospholipid antibodies are more clinically significant than IgM for thrombotic APS, showing stronger associations with thrombosis and higher diagnostic value, while IgM antibodies have independent value primarily in obstetric APS and should be tested routinely in women with pregnancy complications. 1
Key Differences in Clinical Significance
Thrombotic APS
IgG antibodies demonstrate superior clinical utility:
- IgG anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) show stronger correlations with thrombosis compared to IgM isotypes 1, 2
- Higher odds ratios are consistently obtained for IgG versus IgM positivity in thrombotic events 3
- Isolated IgM positivity is rare in thrombotic APS (3.5-5.4% depending on assay platform) 3
IgM has limited independent value in thrombotic disease:
- In multivariate analysis, IgM positivity was not independently associated with thrombosis when adjusted for other aPL 3
- First-line testing for IgM in suspected thrombotic APS is not strictly necessary 1
- However, IgM may be useful as a second-line test for risk stratification, as combined positivity (LA + IgG + IgM) significantly increases thrombotic risk 1, 3
Obstetric APS
IgM has independent diagnostic value in pregnancy complications:
- Isolated IgM positivity is more frequent in obstetric APS (5.7-12.3%) compared to thrombotic APS 3
- Both aCL and aβ2GPI IgM are independent risk factors for pregnancy morbidity 1
- In multivariate analysis, IgM positivity was independently associated with pregnancy morbidity 3
Testing recommendation: In women with suspected obstetric APS, both IgG and IgM should be tested routinely 1
Risk Stratification Value
Triple Positivity
The highest thrombotic risk occurs with triple positivity (LA + IgG + IgM), which is highly associated with both thrombosis and pregnancy morbidity 3. The presence of concordant isotypes (same isotype for both aCL and aβ2GPI) further reinforces clinical probability 1.
Isotype Concordance
When aCL and aβ2GPI are positive for the same isotype, this significantly strengthens the clinical probability of APS, with higher odds ratios compared to mixed isotype positivity 1.
Clinical Pitfalls to Avoid
Don't rely on isolated IgM in thrombotic APS: While isolated IgM can occur, it's rare and has weaker associations with thrombosis. Consider other diagnoses or repeat testing 3
Don't skip IgM testing in obstetric cases: Unlike thrombotic APS, IgM has independent predictive value for pregnancy complications and should always be included 1
Consider specific populations: In certain subgroups like stroke patients, isolated IgM may be more frequent and warrants investigation 1
Thrombocytopenia association: IgM antibodies are significantly associated with thrombocytopenia, which is included in the 2023 ACR/EULAR classification criteria 1
Practical Testing Algorithm
For suspected thrombotic APS:
- Test IgG aCL and aβ2GPI as first-line
- Add IgM testing if risk stratification is needed or if IgG is negative but clinical suspicion remains high
- IgM positivity adds value when combined with other positive aPL
For suspected obstetric APS:
- Always test both IgG and IgM for aCL and aβ2GPI
- IgM has independent diagnostic significance
For risk stratification:
- Triple positivity (LA + IgG + IgM) = highest risk
- Concordant isotypes (both aCL and aβ2GPI same isotype) = higher risk
- Isolated IgM = lower risk in thrombotic APS, but relevant in obstetric APS
Evidence Quality Note
The 2025 ISTH-SSC guidance 1 represents the most current expert consensus, incorporating data from multiple large multicenter studies 3 and meta-analyses 2. The 2023 ACR/EULAR classification criteria 4 assigned low weight to isolated IgM, reflecting its limited role in thrombotic disease while acknowledging ongoing research needs.